Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC1797754154;54155;54156 chr2:178605248;178605247;178605246chr2:179469975;179469974;179469973
N2AB1633649231;49232;49233 chr2:178605248;178605247;178605246chr2:179469975;179469974;179469973
N2A1540946450;46451;46452 chr2:178605248;178605247;178605246chr2:179469975;179469974;179469973
N2B891226959;26960;26961 chr2:178605248;178605247;178605246chr2:179469975;179469974;179469973
Novex-1903727334;27335;27336 chr2:178605248;178605247;178605246chr2:179469975;179469974;179469973
Novex-2910427535;27536;27537 chr2:178605248;178605247;178605246chr2:179469975;179469974;179469973
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: K
  • RefSeq wild type transcript codon: AAA
  • RefSeq wild type template codon: TTT
  • Domain: Ig-114
  • Domain position: 10
  • Structural Position: 14
  • Q(SASA): 0.343
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
K/N None None 0.912 N 0.351 0.255 0.239305524855 gnomAD-4.0.0 1.60552E-06 None None None None N None 0 0 None 0 0 None 0 0 2.87974E-06 0 0
K/Q None None 0.947 N 0.385 0.254 0.263140351381 gnomAD-4.0.0 6.86935E-07 None None None None N None 0 0 None 0 0 None 0 0 9.01656E-07 0 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
K/A 0.4743 ambiguous 0.5927 pathogenic -0.4 Destabilizing 0.737 D 0.353 neutral None None None None N
K/C 0.7405 likely_pathogenic 0.8116 pathogenic -0.669 Destabilizing 0.998 D 0.364 neutral None None None None N
K/D 0.8445 likely_pathogenic 0.8894 pathogenic 0.195 Stabilizing 0.932 D 0.419 neutral None None None None N
K/E 0.4396 ambiguous 0.4981 ambiguous 0.296 Stabilizing 0.837 D 0.317 neutral N 0.443109543 None None N
K/F 0.841 likely_pathogenic 0.8866 pathogenic -0.221 Destabilizing 0.98 D 0.404 neutral None None None None N
K/G 0.7163 likely_pathogenic 0.8066 pathogenic -0.705 Destabilizing 0.932 D 0.392 neutral None None None None N
K/H 0.3789 ambiguous 0.4429 ambiguous -0.742 Destabilizing 0.993 D 0.382 neutral None None None None N
K/I 0.4028 ambiguous 0.4705 ambiguous 0.366 Stabilizing 0.064 N 0.234 neutral N 0.411213343 None None N
K/L 0.4675 ambiguous 0.5256 ambiguous 0.366 Stabilizing 0.584 D 0.348 neutral None None None None N
K/M 0.3112 likely_benign 0.3647 ambiguous -0.057 Destabilizing 0.98 D 0.379 neutral None None None None N
K/N 0.6592 likely_pathogenic 0.7412 pathogenic -0.329 Destabilizing 0.912 D 0.351 neutral N 0.462314167 None None N
K/P 0.8336 likely_pathogenic 0.8842 pathogenic 0.14 Stabilizing 0.993 D 0.421 neutral None None None None N
K/Q 0.209 likely_benign 0.2501 benign -0.338 Destabilizing 0.947 D 0.385 neutral N 0.460447297 None None N
K/R 0.0926 likely_benign 0.0952 benign -0.238 Destabilizing 0.016 N 0.196 neutral N 0.423622493 None None N
K/S 0.5617 ambiguous 0.6895 pathogenic -0.955 Destabilizing 0.773 D 0.296 neutral None None None None N
K/T 0.2041 likely_benign 0.2651 benign -0.655 Destabilizing 0.064 N 0.195 neutral N 0.419176678 None None N
K/V 0.3537 ambiguous 0.426 ambiguous 0.14 Stabilizing 0.037 N 0.166 neutral None None None None N
K/W 0.8262 likely_pathogenic 0.8689 pathogenic -0.157 Destabilizing 0.998 D 0.438 neutral None None None None N
K/Y 0.7449 likely_pathogenic 0.8075 pathogenic 0.148 Stabilizing 0.993 D 0.38 neutral None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.